Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Oxamflatin

HDAC inhibitor
 
ALX-270-379-M001 1 mg 86.00 USD
 
ALX-270-379-M005 5 mg 314.00 USD
Do you need bulk/larger quantities?
 
Potent inhibitor of mammalian HDACs (histone deacetylases) (IC50=15.7nM). Acts as a ligand for the enzyme active site metal ion. Upregulates plasminogen activator inhibitor type 2 (PAI-2) expression with concomitant inhibition of urokinase (u-PA) gene and protein expression in HT-1080 and U-937 cells. Elevates the expression of extracellular matrix proteins fibronectin and gelsolin. Induces apoptosis in P-glyoprotein (Pgp) positive and Pgp negative multidrug resistant cells.

Product Specification

Alternative Name:(2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic acid
 
Formula:C17H14N2O4S
 
MW:342.4
 
CAS:151720-43-3
 
Purity:≥95% (HPLC)
 
Appearance:Tan to yellow solid.
 
Solubility:Soluble in DMSO, methanol or acetonitrile.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:+4°C
 
Handling:Protect from light. Packaged under inert gas. After reconstitution, prepare aliquots and store at -20°C.
 
ALX-270-379 structure
Please mouse over
ALX-270-379 structure

Product Literature References

Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells: K. Huber, et al.; J. Biol. Chem. 286, 22211 (2011), Abstract; Full Text
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors: M.J. Peart, et al.; Cancer Res. 63, 4460 (2003), Abstract;
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity: A.E. Dear & R.L. Medcalf; Biochim. Biophys. Acta 1492, 15 (2000), Abstract;
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase: Y.B. Kim, et al.; Oncogene 18, 2461 (1999), Abstract;
Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD: H. Sonoda, et al.; Oncogene 13, 143 (1996), Abstract;

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

Brochures
Epigenetics
Epigenetics
Download as PDF

All new literature pieces

Recommend this page

 
Keep in touch

©2017 Enzo Life Sciences, Inc.,